Belviq (generic: lorcaserin) is the first weight loss drug to be approved by the Food and Drug Administration (FDA) in over 13 years. The medication works by controlling hunger and appetite and the feeling of satiety. More specifically, the drug works by activating serotonin receptors in the brain that are involved in the regulation of the feelings of satisfaction with food. In clinical trial, the drug has been shown to be very effective. In almost half of study participants on the drug without type 2 diabetes, the average weight loss was 5% of starting weight or about 12 pounds over a year of follow up. The FDA has approved the drug with an indication for weight loss in individuals who are considered obese with a body mass index of 30 or greater or individuals who are considered overweight with a body mass index of 27 or above and have at least one weight related medical condition. These weight-related medical conditions include such diseases as high cholesterol, type 2 diabetes mellitus, or hypertension. There is a concern that the drug may contribute to heart valve defects, but more recent data from the company has shown that this does not occur with the lowest doses of the medication.
Read more about Belviq on the FDA website: FDA approves Belviq to treat some overweight or obese adults
See the following video documentary of a medical journalist’s experience as a participant in the Belviq clinical trial, and the tremendous health benefits that he has seen while losing weight with the help of Belviq: